CEC

The Clinical Trial Centre (CEC) performs clinical studies. CEC has dedicated facilities and updated ophthalmological equipment. Clinical patient-oriented research involves characterizing disease progression and testing new discoveries by carrying out carefully controlled research studies in patients, i. e., clinical trials. This includes testing not only new drugs, but also new methods, devices, imaging and surgical procedures as well as well-designed prospective, observational, longitudinal studies.

SERVICES
  • Randomized clinical trials
  • Clinical research studies
  • Testing new drugs, methods, devices, imaging and surgical procedures
  • Prospective, observational, longitudinal studies.

The Clinical Trial Centre (CEC) performs clinical studies. CEC has dedicated facilities and updated ophthalmological equipment.

Clinical patient-oriented research involves characterizing disease progression and testing new discoveries by carrying out carefully controlled research studies in patients, i. e., clinical trials and other types of clinical studies. This includes testing not only new drugs, but also new methods, devices, imaging and surgical procedures as well as well-designed prospective, observational, longitudinal studies.

Our research is focused in age-related eye diseases with special emphasis on diabetic retinopathy and age-related macular degeneration.

CEC is certified as Clinical Site of Excellence by the EVICR.net – European Vision Institute Clinical Research Network (Clinical Site nº 1), that is a clinical trial centre in ophthalmology that complies with ICH GCP Guidelines with written SOPs. CEC has the necessary equipment and personnel to perform clinical trials and has proven expertise and scientific publications in this area.

Research Focus

Biomarkers of progression of Diabetic Retinopathy
Vision Threatening Complications in Diabetic Retinopathy Progression
Epidemiological characterization of AMD. Characterization of progression of AMD from intermediate to late forms of AMD
Evaluation of novel treatment options for complications of Diabetic Retinopathy
Validation Outcomes and testing treatments for sight threatening Age-Related Macular Degeneration

Areas of expertise

 

Retina:

Identification of phenotypes and biomarkers of retinal disease progression
Testing new methods of early diagnosis of macular edema and retinal vascular disease
Characterisation of responders and non-responders to new available therapies of retinal disease
Characterization of phenotypes of diabetic retinopathy
Neurovascular degeneration in age-related disease

 

Glaucoma:

Evaluation of new drugs for glaucoma treatment

 

Other:

Optical Coherence Tomography in the diagnosis of neurological diseases
Diagnostic correlations in imaging between brain and retina
Eye fundus imaging as a predictor of systemic vascular disease
Neurovascular degeneration in age-related disease

  • Director

    José Cunha-Vaz

  • Investigator

    Ana Patrícia Oliveira

    Andreia Rosa

    Conceição Lobo

    Inês Laíns

    Inês Pereira Marques

    Isabel Pires

    João Figueira

    João Pedro Marques

    Joaquim Neto Murta

    José Ricardo Araújo

    José Costa

    Júlia Veríssimo

    Marco Marques

    Maria João Quadrado

    Maria Luísa Ribeiro

    Maria Luz Cachulo

    Miguel Amaro

    Pedro Faria

    Rufino Silva

  • Laboratory Technician

    Filipe Martins

  • Study Coordinator

    Catarina Eloy

    Filipe Martins

    Marcela Pascoal

    Sandra Cristina Pardal

  • Technician for Diagnostic Procedures

    Ana Maria Nunes

    Ana Rita Santos

    Marta Lopes

    Sílvia Simão

  • Nurse

    Aida Cristina Vitorino

    Eugénia Cardoso

    Maria do Céu Simões

    Paulo Marques

  • Pharmacist

    Maria Viegas Nascimento

    Patrícia Barreto

  • Secretary

    Sandra Cristina Pardal

  • Director Assistant

    Patrícia Barreto

  • Clients

    ‣ Alcon

    ‣ Alimera

    ‣ Allergan

    ‣ Bausch & Lomb

    ‣ Bayer

    ‣ Chiltern

    ‣ Eurotrials

    ‣ EyeTech

    ‣ Farmalabor

    ‣ IRIS Pharma

    ‣ Lilly

    ‣ Merck Sharp & Dohme

    ‣ Novartis

    ‣ OM Pharma

    ‣ Pfizer

    ‣ Pharmaceutical Product Development

    ‣ Pharmacia Corporation

    ‣ Sanofi-Aventis

    ‣ Servier

    ‣ Théa

CONTACTS

José Cunha-Vaz

Phone: +351 239480128
Fax: +351 239 480117

mail: aibili@aibili.pt